NewAmsterdam Pharma Company (NAMS) Jefferies Global Healthcare Conference 2025 summary

Key clinical and scientific updates

• Three phase III trials reported positive results, boosting confidence in regulatory approval and market readiness for obicetrapib.

• Recent cardiology conferences highlighted obicetrapib's benefits in reducing Lp(a), HbA1c, and diabetes risk, with further analyses planned at upcoming conferences.

• Obicetrapib targets multiple risk factors in ASCVD, including LDL, Lp(a), remnant cholesterol, and small LDL particles, aiming to address residual risk beyond current therapies.

• Phase III studies showed a 45% reduction in Lp(a) for patients not eligible for Lp(a)-targeted agents, with the VINCENT study underway to assess combination effects with PCSK9 inhibitors.

• The BROADWAY study revealed a 21% MACE benefit at one year, exceeding expectations and prompting further investigation into the drivers of this effect.

Market landscape and future positioning

• The addressable market includes tens of millions with elevated LDL, Lp(a), diabetes, or kidney dysfunction, with obicetrapib positioned as a versatile option across these groups.

• Combination therapies and fixed-dose approaches are expected to become more prominent, with obicetrapib offering potential as a preferred therapy due to its broad efficacy and safety profile.

• Engagement with physicians and payers globally indicates strong demand and a favorable perception of obicetrapib's profile.

• The drug's once-daily, low-dose oral formulation and safety make it suitable for asymptomatic patients at risk of future events.

• Regulatory discussions are ongoing regarding label claims, especially for Lp(a) and MACE endpoints, with commercial implications considered in endpoint selection.

Financial and operational outlook

• Over $810 million in cash as of Q1, following two financings totaling $700 million last year, ensuring completion of clinical trials and readiness for global launch.

• Funding supports expansion of manufacturing capabilities and inventory, with plans to independently launch in the U.S. around 2027.

• Additional studies, including the Rembrandt imaging study, are underway to further support marketing and clinical positioning.